{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:31:18Z","timestamp":1791729078375,"version":"4.3.4"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00917","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T01:25:06Z","timestamp":1591147506000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":74,"title":["Complement Inhibitor Therapy for Myasthenia Gravis"],"prefix":"10.3389","volume":"11","author":[{"given":"Khaled","family":"Albazli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J.","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1056\/NEJMc1701027","article-title":"Myasthenia gravis","volume":"376","author":"Gilhus","year":"2017","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1073\/pnas.75.7.3422","article-title":"Effect of myasthenic patients' immunoglobulin on acetylcholine receptor turnover: selectivity of degradation process","volume":"75","author":"Drachman","year":"1978","journal-title":"Proc Natl Acad Sci USA."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJM197701202960301","article-title":"Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice","volume":"296","author":"Toyka","year":"1977","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00005072-197803000-00008","article-title":"Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis","volume":"37","author":"Sahashi","year":"1978","journal-title":"J Neuropathol Exp Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/nyas.13555","article-title":"Acetylcholine receptor antibody-mediated animal models of myasthenia gravis and the role of complement","volume":"1413","author":"Kusner","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1055\/s-0038-1660500","article-title":"Pathogenic mechanisms and clinical correlations in autoimmune myasthenic syndromes","volume":"38","author":"Cetin","year":"2018","journal-title":"Semin Neurol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09498-4","article-title":"Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review","author":"Chamberlain","year":"2019","journal-title":"J Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest."},{"key":"B13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement regulators and inhibitory proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/mus.23448","article-title":"Cell surface complement regulators moderate experimental myasthenia gravis pathology","volume":"47","author":"Kusner","year":"2013","journal-title":"Muscle Nerve."},{"key":"B15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/(SICI)1097-4598(199701)20:1<92::AID-MUS12>3.0.CO;2-3","article-title":"Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers","volume":"20","author":"Navenot","year":"1997","journal-title":"Muscle Nerve."},{"key":"B16","doi-asserted-by":"publisher","first-page":"12062","DOI":"10.1073\/pnas.211257298","article-title":"Extraocular muscle is defined by a fundamentally distinct gene expression profile","volume":"98","author":"Porter","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195342185.003.0014","article-title":"The complement hypothesis to explain preferential involvement of extraocular muscle by myasthenia gravis","volume-title":"Advances in Understanding Mechanisms and Treatment of Infantile Forms of Nystagmus.","author":"Kaminski","year":"2008"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology."},{"key":"B19","first-page":"267","article-title":"Howard, Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"Engel","year":"1977","journal-title":"Mayo Clin Proc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","article-title":"Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis","volume":"39","author":"Sahashi","year":"1980","journal-title":"J Neuropathol Exp Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.08.002","article-title":"The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo","volume":"158","author":"Romi","year":"2005","journal-title":"J Neuroimmunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1212\/WNL.35.12.1748","article-title":"Complement-dependent lysis of cultured rat myotubes by myasthenic immunoglobulins","volume":"35","author":"Ashizawa","year":"1985","journal-title":"Neurology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0303-8467(93)90103-N","article-title":"Soluble terminal complement components in human myasthenia gravis","volume":"95","author":"Barohn","year":"1993","journal-title":"Clin Neurol Neurosurg."},{"key":"B24","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1136\/jnnp.41.8.746","article-title":"Myasthenia gravis: further electrophysiological and ultrastructural analysis of transmission failure in the mouse passive transfer model","volume":"41","author":"Toyka","year":"1978","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1212\/WNL.30.7.760","article-title":"Passive transfer of human myasthenia gravis to rats: 1. Electrophysiology of the developing neuromuscular block","volume":"30","author":"Howard","year":"1980","journal-title":"Neurology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.expneurol.2015.02.025","article-title":"Guidelines for pre-clinical assessment of the acetylcholine receptor\u2013specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs","volume":"270","author":"Kusner","year":"2015","journal-title":"Exp Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1084\/jem.147.4.973","article-title":"Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis","volume":"147","author":"Lennon","year":"1978","journal-title":"J Exp Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1365-2249.2006.03198.x","article-title":"Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats","volume":"146","author":"Chamberlain-Banoub","year":"2006","journal-title":"Clin Exp Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"T\u00fcz\u00fcn","year":"2003","journal-title":"J Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.molimm.2017.05.012","article-title":"Intracellular complement - the complosome - in immune cell regulation","volume":"89","author":"Arbore","year":"2017","journal-title":"Mol Immunol"},{"key":"B31","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.4049\/jimmunol.140.8.2589","article-title":"C5 gene influences the development of murine myasthenia gravis","volume":"140","author":"Christadoss","year":"1988","journal-title":"J Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.expneurol.2004.06.005","article-title":"Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis","volume":"189","author":"Kaminski","year":"2004","journal-title":"Exp Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin Exp Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1172\/JCI0216086","article-title":"Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection","volume":"110","author":"Lin","year":"2002","journal-title":"J Clin Invest."},{"key":"B35","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.4049\/jimmunol.142.8.2654","article-title":"Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6","volume":"142","author":"Biesecker","year":"1989","journal-title":"J Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0165-5728(96)00144-0","article-title":"Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis","volume":"71","author":"Piddlesden","year":"1996","journal-title":"J Neuroimmunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","article-title":"Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis","volume":"179","author":"Zhou","year":"2007","journal-title":"J Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ana.21536","article-title":"Novel complement inhibitor limits severity of experimentally myasthenia gravis","volume":"65","author":"Soltys","year":"2009","journal-title":"Ann Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mus.23247","article-title":"Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis","volume":"45","author":"Song","year":"2012","journal-title":"Muscle Nerve."},{"key":"B40","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/mus.24057","article-title":"Targeting therapy to the neuromuscular junction: proof of concept","volume":"49","author":"Kusner","year":"2014","journal-title":"Muscle Nerve."},{"key":"B41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jaut.2013.01.003","article-title":"Complement C2 siRNA mediated therapy of myasthenia gravis in mice","volume":"42","author":"Huda","year":"2013","journal-title":"J Autoimmun."},{"key":"B42","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.omtm.2019.04.009","article-title":"Investigational RNAi therapeutic targeting C5 is efficacious in pre-clinical models of myasthenia gravis","volume":"13","author":"Kusner","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CND.0000000000000257","article-title":"Impact of refractory myasthenia gravis on health-related quality of life","volume":"20","author":"Boscoe","year":"2019","journal-title":"J Clin Neuromuscul Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mus.26114","article-title":"Burden of illness in patients with treatment refractory myasthenia gravis","volume":"58","author":"Engel-Nitz","year":"2018","journal-title":"Muscle Nerve"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1756286419832242","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord."},{"key":"B46","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J Clin Neuromuscul Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Zilucoplan, a subcutaneously self-administered peptide inhibitor of complement component (C5), for the treatment of generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1182\/blood.V126.23.939.939","article-title":"Preclinical evaluation of RA101495, a potent cyclic peptide inhibitor of C5 for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"126","author":"Ricardo","year":"2015","journal-title":"Blood."},{"key":"B52","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve."},{"key":"B54","first-page":"S97","article-title":"Eculizumab shows consistent improvement across quantitative myasthenia gravis test muscle groups","volume":"58","author":"Mantegazza","year":"2018","journal-title":"Muscle Nerve."},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P5.2-080","article-title":"Changes in concomitant immunosuppressive therapy use during a phase 3 open-label study of eculizumab in adults with generalized myasthenia gravis: an interim analysis (P5.2-080)","volume":"92","author":"Nowak","year":"2019","journal-title":"Neurology."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","article-title":"Eculizumab improves fatigue in refractory generalized myasthenia gravis","volume":"28","author":"Andersen","year":"2019","journal-title":"Qual Life Res."},{"key":"B57","first-page":"58","article-title":"Response to eculizumab in myasthenia gravis patients recently treated with chronic IVIG","author":"Jacob","year":"2018","journal-title":"Muscle Nerve."},{"key":"B58","first-page":"S98","article-title":"Eculizumab reduces myasthenia gravis exacerbation rates","volume":"58","author":"Jacob","year":"2018","journal-title":"Muscle Nerve."},{"key":"B59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.13544","article-title":"Rationale for the clinical guidelines for myasthenia gravis in Japan","volume":"1413","author":"Murai","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B62","first-page":"S97","article-title":"\u201cMinimal symptom expression\u201d with eculizumab in myasthenia gravis","volume":"58","author":"Vissing","year":"2018","journal-title":"Muscle Nerve"},{"key":"B63","first-page":"S133","article-title":"Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses","volume":"60","author":"Howard","year":"2019","journal-title":"Muscle Nerve."},{"key":"B64","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1212\/NXI.0000000000000645","article-title":"SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody","volume":"7","author":"Huda","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e127167","DOI":"10.1172\/jci.insight.127167","article-title":"Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients","volume":"4","author":"Takata","year":"2019","journal-title":"JCI Insight."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00917\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T17:23:22Z","timestamp":1722965002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00917\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2020.00917"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00917","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"article-number":"917"}}